Live attenuated influenza vaccine induces broadly cross-reactive mucosal antibody responses to different influenza strains in tonsils

Live attenuated influenza vaccine induces broadly cross-reactive mucosal antibody responses to different influenza strains in tonsils

Intranasal live attenuated influenza vaccine (LAIV) was used to stimulate tonsillar monocular cells (MNCs) following isolation. Haemagglutinin (HA) proteins of several influenza strains were used for the detection of HA-specific IgG, IgM and IgA antibodies using ELISA. Significant anti-sH1N1 HA IgG...

Full description

Bibliographic Details
Main Authors:	Waleed H. Mahallawi, Qibo Zhang
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Saudi Journal of Biological Sciences
Subjects:	B cells responses Cross reactive immunity Influenza viruses LAIV Intranasal vaccine NALT
Online Access:	http://www.sciencedirect.com/science/article/pii/S1319562X23002541

Similar Items

Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections
by: D. Korenkov, et al.
Published: (2018-04-01)

Immune responses after live attenuated influenza vaccination
by: Kristin G.-I. Mohn, et al.
Published: (2018-03-01)

BCG vaccine-induced mucosal humoral immunity in human nasal associated lymphoid tissue
by: Talal M. Aljeraisi, et al.
Published: (2023-08-01)

Mutation E48K in PB1 Polymerase Subunit Improves Stability of a Candidate Live Attenuated Influenza B Virus Vaccine
by: Jongsuk Mo, et al.
Published: (2021-07-01)

Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein
by: C. Joaquín Cáceres, et al.
Published: (2021-06-01)

Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review
by: Kenneth Sik-Kwan Chan, et al.
Published: (2022-09-01)

The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection
by: N. R. Makhmudova, et al.
Published: (2019-12-01)

Pandemic H1N1 influenza virus triggers a strong T helper cell response in human nasopharynx-associated lymphoid tissues
by: Waleed H. Mahallawi, et al.
Published: (2024-03-01)

FluB-RAM and FluB-RANS: Genome Rearrangement as Safe and Efficacious Live Attenuated Influenza B Virus Vaccines
by: Stivalis Cardenas-Garcia, et al.
Published: (2021-08-01)

Live attenuated influenza A virus vaccine expressing an IgA-inducing protein protects pigs against replication and transmission
by: Daniela S. Rajao, et al.
Published: (2023-02-01)

Protection of children against influenza: Emerging problems
by: Nicola Principi, et al.
Published: (2018-03-01)

A Mutated PB1 Residue 319 Synergizes with the PB2 N265S Mutation of the Live Attenuated Influenza Vaccine to Convey Temperature Sensitivity
by: Andrew Cox, et al.
Published: (2020-10-01)

Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model
by: Ekaterina Stepanova, et al.
Published: (2021-01-01)

Novel Approaches for The Development of Live Attenuated Influenza Vaccines
by: Pilar Blanco-Lobo, et al.
Published: (2019-02-01)

The influence of seasonal influenza viruses biological features on the effectiveness of development strains for live influenza vaccine
by: N. V. Larionova, et al.
Published: (2019-11-01)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
by: Dominic Thorrington, et al.
Published: (2017-09-01)

Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada’s experience with the live-attenuated influenza vaccine
by: Linlu Zhao, et al.
Published: (2021-05-01)

Immunogenicity and Protective Efficacy of Seasonal Human Live Attenuated Cold-Adapted Influenza Virus Vaccine in Pigs
by: Barbara Holzer, et al.
Published: (2019-11-01)

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method
by: Yunfeng Long, et al.
Published: (2018-03-01)

Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus
by: Yu-Jin Jung, et al.
Published: (2020-12-01)

Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice
by: Jorma Hinkula, et al.
Published: (2019-07-01)

Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
by: Michael J. Moser, et al.
Published: (2023-06-01)

Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use
by: Aitor Nogales, et al.
Published: (2022-07-01)

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults
by: Irina Kiseleva, et al.
Published: (2020-06-01)

Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity
by: Jocelyn G. Labombarde, et al.
Published: (2022-03-01)

Optimized properties of live vaccine influenza reassortant strains obtained by reverse genetics
by: N. V. Larionova, et al.
Published: (2023-12-01)

Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections
by: Cynthia Calzas, et al.
Published: (2019-07-01)

T and B Cell Immune Responses to Influenza Viruses in Pigs
by: Barbara Holzer, et al.
Published: (2019-02-01)

Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies
by: Rachael Keating, et al.
Published: (2020-12-01)

Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis
by: Giulia Perego, et al.
Published: (2021-09-01)

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics
by: Kaori Sano, et al.
Published: (2018-08-01)

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
by: Andrea N. Loes, et al.
Published: (2020-09-01)

Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza
by: Junwei eLi, et al.
Published: (2015-04-01)

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs
by: Santosh Dhakal, et al.
Published: (2018-05-01)

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
by: Seiya Yamayoshi, et al.
Published: (2017-03-01)

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults
by: Ruiqi Zhang, et al.
Published: (2023-03-01)

Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site
by: Tatiana Kotomina, et al.
Published: (2018-12-01)

Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults
by: Philip Meade, et al.
Published: (2020-02-01)

Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG
by: Luis Ontiveros-Padilla, et al.
Published: (2023-03-01)

Correlation of C-reactive protein to severity of symptoms in acute influenza A infection
by: John P Haran, et al.
Published: (2012-01-01)